18 children lost their lives in Uzbekistan after consuming Doc-1 Max tablets and cough syrup. Reportedly, these tablets and syrup were manufactured by a Noida-based company named Marion Biotech. India has initiated a probe into the claims made by the health ministry of Uzbekistan. Offices have stated that a thorough and deep investigation will be carried out regarding this case.
The Health Ministry of Uzbekistan revealed that concerned doctors have stated that all the children who were admitted to the hospital due to sudden deterioration in their health had one thing in common that is the consumption of Doc-1 Max tablets or syrups. They further revealed that some parents exceeded the required amount of dosage and were giving this cough syrup to their children as an anti-cold remedy. Ministry of health revealed that all the deceased were consuming this medication from last 2-7 days that also 4-5 times a day which is not prescribed by the doctors.
Uzbekistan got a laboratory test conducted for the cough syrup which revealed that it consists of ethylene glycol which is a toxic substance. India has now carried out a joint operation including Central Drugs Standard Control Organization & Uttar Pradesh Drugs Controlling and Licensing Authority to test these medications. They have taken samples of Doc-1 Max tablets and cough syrups to check what caused the death of so many young children.
Uzbekistan for the time being has withdrawn the sale of Doc-1 Max tablets and cough syrups from all the pharmacies across the country to prevent future deaths. They have further advised the general public not to consume the same.
Earlier also Haryana-based Maiden Pharma was under probe as their medicines and cough syrup became the reason for the death of 70 children in Gambia. During this, it was stated that the medication contained the same chemical and was not added with adequate safeguards.
Reportedly, the probe is still on the same while health ministries of both countries are trying their level best to solve the same problem. Further information will only be provided after the investigation sees some development.